MPS PHARMAA LIMITED

As of June 30, 2026, MPS PHARMAA LIMITED carries a market capitalization of 34.59M, placing it among publicly traded companies globally. Its enterprise value stands at 34.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, MPS PHARMAA LIMITED has 19.11M shares outstanding.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 18.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, MPS PHARMAA LIMITED recorded an income tax benefit of -293,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -10.67M and -10.38M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 19, 2026, MPS PHARMAA LIMITED's stock has gained approximately 0.48% over the past 52 weeks. The 50-day moving average sits at 1.91, while the 200-day moving average is 2.54.

Over the twelve months ended June 30, 2026, MPS PHARMAA LIMITED generated - - in revenue and converted that into -10.38M in net income, yielding earnings per share of -0.55. EBITDA reached -9.56M, while operating income came in at -9.48M.